Trial record 1 of 1 for:
BBI-20201001
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04278144 |
|
Recruitment Status :
Recruiting
First Posted : February 20, 2020
Last Update Posted : February 29, 2024
|
Sponsor:
Bolt Biotherapeutics, Inc.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bolt Biotherapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2025 |
| Estimated Study Completion Date : | October 31, 2026 |